Applica

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number Filing Date		10092261
		2002-03-07
First Named Inventor	Mikko	o Makipaa
Art Unit		2173
Examiner Name	D. Bo	onshock
Attorney Docket Number		004770.00042

Examiner Initial*	No Patent Number Nind Issue Date Name of Patentee of Applicant Releva		Columns,Lines where ant Passages or Relevant Appear					
	1	5886689		1999-03-23	Chee et al.			
	2	5437036	А	1995-07-25	Stamps et al.			
If you wis	h to a	dd additional U.S. Paten	t citatio	n information p	lease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document Pages, Columns, Lines where Relevant Passages or Releva Figures Appear			
	1	20020196294	A1	2002-12-26	Sesek			
	2	20020055992	A1	2002-05-09	King et al.			
	3	20030203731	A1	2003-10-30	King et al.			
	4	20030169306	A1	2003-09-11	Makipaa et al.			

U.S.PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

A

E

pplication Number		10092261
iling Date		2002-03-07
irst Named Inventor Mikko		Makipaa
rt Unit		2173
xaminer Name D. Bo		enshock
ttomey Docket Number		004770.00042

Date Considered

	ľ	20010013101	1 20070	722	, mg				
If you wish	h to a	dd additional U.S. Publi	shed Application	citatio	n information p	olease click the Add	d buttor	n. Add	
			FORE	GN PAT	TENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code4	Publication Date	Name of Patentee Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	т5
	1	10065211	DE	A1	2002-05-16	Sedima AG			
	2	0733983	EP	A2	1996-09-25	AT&T IPM Corp.			
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add	button		
NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Initials* Cite (Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, dry and/or country where published.							Τs		
	1								
If you wish	If you wish to add additional non-patent literature document citation information please click the Add button Add								
EYAMINED SIGNATURE									

See find. Code of USPTO Planto Documents at year, USPTO, CODY on MPEP 901.04. * Enter office that sweet the document, by the lose before code (WIPO) Standard ST3.3.* * Fraginese plant documents, the includion to the year of the reging on the Emperor mant processor the senior increase for the plant document. * Mind of coursent by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to plant a check mark here if Employin tanguage streamlisten as standards.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10092261	
Filing Date		2002-03-07	
First Named Inventor	Mikko Makipaa		
Art Unit		2173	
Examiner Name	D. Bonshock		
Attorney Docket Number		004770 00042	

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make	the appropriate	selection(s):
---------------	----------	------------------	-----------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information siclosure statement. See 37 CFR 197(e)(1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 15(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement.

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Anthony W. Kandare/	Date (YYYY-MM-DD)	2006-09-29					
Name/Print	Anthony W. Kandara	Registration Number	48830					

This collection of information is required by 3 T CPR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 and 3 T CPR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, U.S. Operatment of Comments of Officer, U.S. Patient and Trademark Office, u.S. Operatment of Comments. P. D. 8t. 1450, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application port to public insepticines or an issuand patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.